Trial Profile

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Actinium 225 rosopatamab (Primary) ; Pembrolizumab (Primary) ; Apalutamide; Darolutamide; Enzalutamide
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

03 Feb 2026 Status changed from recruiting to active, no longer recruiting.
25 Sep 2025 Planned End Date changed from 1 Jun 2028 to 1 Dec 2029.
25 Aug 2025 Planned primary completion date changed from 1 Jun 2026 to 1 Oct 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com